Estrella Immunopharma (NASDAQ:ESLA) Trading 4.9% Higher – Should You Buy?

Estrella Immunopharma, Inc. (NASDAQ:ESLA)’s stock price rose 4.9% on Thursday . The company traded as high as $0.96 and last traded at $0.92. Approximately 16,938 shares traded hands during trading, a decline of 87% from the average daily volume of 126,296 shares. The stock had previously closed at $0.88.

Wall Street Analyst Weigh In

Separately, D. Boral Capital reissued a “buy” rating and set a $16.00 target price on shares of Estrella Immunopharma in a research report on Thursday, May 29th.

Estrella Immunopharma Trading Up 4.9%

The firm has a market cap of $33.42 million, a price-to-earnings ratio of -3.55 and a beta of 0.36. The business’s 50-day simple moving average is $1.00 and its two-hundred day simple moving average is $1.04.

Institutional Trading of Estrella Immunopharma

A hedge fund recently raised its stake in Estrella Immunopharma stock. Geode Capital Management LLC lifted its stake in shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) by 22.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 93,418 shares of the company’s stock after buying an additional 16,862 shares during the quarter. Geode Capital Management LLC owned about 0.26% of Estrella Immunopharma worth $106,000 as of its most recent filing with the Securities & Exchange Commission. 0.35% of the stock is owned by hedge funds and other institutional investors.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.